Home › Funds › Frazier Life Sciences Management, L.P. › BCRX

Frazier Life Sciences Management, L.P. position in BCRX

BIOCRYST PHARMACEUTICALS INC · Health Care

Frazier Life Sciences Management, L.P. reported holding 4,009,240 shares of BCRX (BIOCRYST PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$40.1M, representing 0.87% of its reported portfolio and ranking #23 among its reported holdings. Frazier Life Sciences Management, L.P. has disclosed BCRX holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

Latest position (Q2 2026)4.01M sh
Reported value held$40.09M
Portfolio Weight0.87%
First reportedQ1 2026
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Frazier Life Sciences Management, L.P.'s BCRX position evolved

Frazier Life Sciences Management, L.P. first disclosed a stake in BCRX in Q1 2026 at 4,009,240 shares (US$38.2M). The position peaked in Q2 2026 at 4,009,240 shares, worth US$40.1M. Across 2 filings, Frazier Life Sciences Management, L.P. held the position steady without any share-count change. The most recent filing (Q2 2026) shows 4,009,240 shares valued at US$40.1M.

Quarter by quarter

QuarterSharesValueChange
Q1 2026 4.01M $38.17M New
Q2 2026 4.01M $40.09M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BCRX and 13F data

BCRX (BIOCRYST PHARMACEUTICALS INC) is a Health Care company. 46 other funds we track also report a position in BCRX — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$158.3M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$151.0M), TCG Crossover Management, LLC (US$110.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BCRX

All BCRX fund holders →

FAQ

How long has Frazier Life Sciences Management, L.P. held BCRX?

Frazier Life Sciences Management, L.P. has disclosed BCRX holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

What is Frazier Life Sciences Management, L.P.'s current position in BCRX?

As of Q2 2026, Frazier Life Sciences Management, L.P. holds 4.01M shares of BCRX (BIOCRYST PHARMACEUTICALS INC), valued at $40.09M, representing 0.87% of its reported portfolio and ranking #23.

Has Frazier Life Sciences Management, L.P. been buying or selling BCRX?

In the latest 13F filing (Q2 2026), Frazier Life Sciences Management, L.P. held unchanged its position in BCRX. The position peaked in Q2 2026 at 4.01M shares.

Which other funds hold BCRX?

Other major institutional holders of BCRX include RA CAPITAL MANAGEMENT, L.P., DEERFIELD MANAGEMENT COMPANY, L.P., TCG Crossover Management, LLC, among 46 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.